William M. Armstead, BA, MS, PhD
Research Professor of Anesthesiology and Critical Care
Department: Anesthesiology and Critical Care
Graduate Group Affiliations
Contact information
Department of Anesthesiology and Critical Care
3620 Hamilton Walk, JM3
Philadelphia, PA 19104-4283
3620 Hamilton Walk, JM3
Philadelphia, PA 19104-4283
Office: 215-573-3674
Fax: 215-349-5078
Fax: 215-349-5078
Email:
armsteaw@uphs.upenn.edu
armsteaw@uphs.upenn.edu
Publications
Links
Search PubMed for articles
Pharmacological Sciences Graduate Group Faculty
Department of Anesthesiology and Critical Care
Search PubMed for articles
Pharmacological Sciences Graduate Group Faculty
Department of Anesthesiology and Critical Care
Education:
B.A. (Biochemistry)
University of Pennsylvania, 1979.
M.S. (Pharmacology)
Tulane University, 1983.
Ph.D. (Pharmacology)
Tulane University, 1985.
Permanent linkB.A. (Biochemistry)
University of Pennsylvania, 1979.
M.S. (Pharmacology)
Tulane University, 1983.
Ph.D. (Pharmacology)
Tulane University, 1985.
Description of CVI Expertise
CVI Program Unit(s):Cardiovascular Development / Congenital Heart Disease
Channel Biology / Electrophysiology
Thrombosis / Hemostasis
CVI Research Description:
Dr. Armstead's research focuses on characterizing mechanisms important in the control of cerebral hemodynamics under physiologic and pathologic conditions such as traumatic brain injury (TBI), stroke, and cerebral hypoxia/ischemia, particularly in the newborn. Current projects focus on interactions between the NMDA receptor and plasminogen activators after TBI, optimizing the efficacy/toxicity ratio of tPA, the only FDA approved treatment for stroke and translational research concerning the roles of sex and age in outcome after pediatric TBI.
Selected Publications
Armstead WM, Ganguly K, Kiessling JW, Chen XH, Smith DH, Higazi AAR, Cines DB, Bdeir K, Zaitsev S, Muzykantov VR. : RBC-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK. J Cereb Blood Flow Metab 29: 1463-1474, 2009.Armstead WM, DB Cines, K Bdeir, Y Bdeir, SC Stein, AAR Higazi.: uPA modulates the age dependent effect of brain injury on cerebral hemodynamics through LRP and ERK MAPK. J Cereb Blood Flow Metab 29: 524-533, 2009.
Kiessling JW, DB Cines, AAR Higazi, WM Armstead. : Inhibition of integrin αVβ3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia. Am J Physiol (296), H862-H867, 2009.
Armstead WM, DB Cines, K Bdeir, I Kulikovskaya, SC Stein, A Higazi: uPA impairs cerebrovasodilation after hypoxia/ischemia through LRP and ERK MAPK. Brain Res 1231: 121-131, 2008.
Armstead WM, AJ Christine, AA Higazi, DB Cines: uPA impairs SNP and PGE2 cerebrovasodilation after brain injury through activation of LRP and ERK MAPK. J Neurotrauma 25: 1375-1381, 2008.
Armstead WM, and MS Vavilala.: Adrenomedullin reduces gender dependent loss of hypotensive cerebrovasodilation after newborn brain injury through activation of ATP dependent K channels. J Cereb Blood Flow Metab 27: 1702-1709, 2007.
Armstead WM.: Differential activation of ERK, p38, and JNK MAPK by nociceptin orphanin FQ in the potentiation of prostaglandin cerebrovasoconstriction after brain injury. Eur J Pharmacol 529: 129-135, 2006.
Armstead WM, T Nassar, S Akkawi, DH Smith, XH Chen, DB Cines, and AAR Higazi. : Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nature Neuroscience 9: 1150-1155, 2006.
Baranov D and WM Armstead. : Nitric oxide contributes to AT2 but not AT1 angiotensin II receptor-mediated vasodilation of porcine pial arteries and arterioles. Eur J Pharmacol 525: 112-116, 2005.
» Top